The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Issues in Outcomes Research: An Overview of Randomization Techniques for Clinical Trials
Kang, M., Ragan, B. G., & Park, J.-H. (2008) · Journal of Athletic Training · doi:10.4085/1062-6050-43.2.215 · Cited by 555 · cited 1×
“The bottles were numbered using the block method [26] in a 1:1 ratio in the laboratory where cannabidiol was produced, and none of the clinical investigators had any approach to the code; patients were randomly assigned to receive either cannabidiol or placebo in the form of oil.”
MethodMechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · cited 1×
“Because CBD lacks any cognitive and psychoactive actions and has an excellent tolerability profile in humans [10], it seems an ideal candidate for therapeutic use.”
BackgroundCannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · cited 1×
“CBD displays potent anti-inflammatory and immunomodulatory properties, described both in acute and in chronic animal models of inflammation [11, 12].”
BackgroundCannabidiol attenuates deficits of visuospatial associative memory induced by Δ9tetrahydrocannabinol
Wright, M. J., Vandewater, S. A., & Taffe, M. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12199 · Cited by 72 · cited 2×
“5 mg/kg) of cannabidiol was shown to be effective in ameliorating side effects of THC [23].”
BackgroundInfluential
Cited by
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01365 · Cited by 560
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals
Williamson, E. M., Liu, X., & Izzo, A. A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14943 · Cited by 304
Abrams, D. I. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.003 · Cited by 296
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., Freeman, T. P., & McGuire, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0667-2 · Cited by 294
Metadata
- Authors
- Naftali, T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M., Laish, I., Benjaminov, F., & Konikoff, F. M.
- Venue
- Digestive Diseases and Sciences
- Published
- 2017-03-27
- Volume
- 62
- Issue
- 6
- Pages
- 1615-1620
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2603876369
- Cited by
- 216
- References
- 6
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial. https://app.cochat.ai/papers/10.1007/s10620-017-4540-z
- The paper
- Naftali, T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M., Laish, I., Benjaminov, F., & Konikoff, F. M. (2017). Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-017-4540-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
